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Abstract 
Glioblastoma (GBM) is the most lethal primary brain tumor characterized by significant cellular heterogeneity, namely 
tumor cells, including GBM stem-like cells (GSCs) and differentiated GBM cells (DGCs), and non-tumor cells such as 
endothelial cells, vascular pericytes, macrophages, and other types of immune cells. GSCs are essential to drive tumor 
progression, whereas the biological roles of DGCs are largely unknown. In this study, we focused on the roles of 
DGCs in the tumor microenvironment. To this end, we extracted DGC-specific signature genes from transcriptomic 
profiles of matched pairs of in vitro GSC and DGC models. By evaluating the DGC signature using single cell data, 
we confirmed the presence of cell subpopulations emulated by in vitro culture models within a primary tumor. The 
DGC signature was correlated with the mesenchymal subtype and a poor prognosis in large GBM cohorts such as 
The Cancer Genome Atlas and Ivy Glioblastoma Atlas Project. In silico signaling pathway analysis suggested a role of 
DGCs in macrophage infiltration. Consistent with in silico findings, in vitro DGC models promoted macrophage migra-
tion. In vivo, coimplantation of DGCs and GSCs reduced the survival of tumor xenograft-bearing mice and increased 
macrophage infiltration into tumor tissue compared with transplantation of GSCs alone. DGCs exhibited a significant 
increase in YAP/TAZ/TEAD activity compared with GSCs. CCN1, a transcriptional target of YAP/TAZ, was selected from 
the DGC signature as a candidate secreted protein involved in macrophage recruitment. In fact, CCN1 was secreted 
abundantly from DGCs, but not GSCs. DGCs promoted macrophage migration in vitro and macrophage infiltration 
into tumor tissue in vivo through secretion of CCN1. Collectively, these results demonstrate that DGCs contribute to 
GSC-dependent tumor progression by shaping a mesenchymal microenvironment via CCN1-mediated macrophage 
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Introduction
Glioblastoma (GBM) is the most aggressive and lethal 
primary brain tumor [33]. Current standard-of-care, 
including surgery, radiotherapy, and chemotherapy, offers 
minimal clinical benefits for GBM patients with median 
survival of less than 16 months [49]. The basis of thera-
peutic failure is the significant inter- and intra-tumoral 
heterogeneity of GBM [34, 38, 48, 55, 56]. One aspect of 
heterogeneity is reflected by the transcriptional subtypes. 
GBMs have been stratified by bulk gene expression pro-
files into at least three subtypes, namely proneural, clas-
sical, and mesenchymal subtypes [55, 56]. Among these 
subtypes, the mesenchymal subtype is associated with 
the worst prognosis and the presence of tumor-associ-
ated macrophages/microglia [39, 56].
Another aspect of heterogeneity is reflected by the 
developmental state of GBM cells in the tumor. In this 
context, GBM stem-like cells (GSCs) present at the apex 
of cellular hierarchies and give rise to differentiated GBM 
cells (DGCs) [1, 23]. GSCs possess capacities for self-
renewal, differentiation, and tumor propagation in  vivo 
and exhibit preferential resistance to radiotherapy and 
chemotherapies [1, 13, 23]. GSCs are essential to drive 
tumor progression, but the importance of DGCs had 
been dismissed until a recent study showed that DGCs 
also contribute to tumor progression in collaboration 
with GSCs [57]. This study highlighted the potential 
importance of DGCs in GBM propagation.
The GBM microenvironment consists of heterogene-
ous cells, namely tumor cells, including GSCs and DGCs, 
and non-tumor cells including endothelial cells, vascu-
lar pericytes, tumor-associated macrophages, and other 
immune cells [11, 16, 22, 46]. Macrophages are an abun-
dant cellular component of the GBM microenvironment 
and play multiple roles in GBM progression [15, 22, 46]. 
Tumor-associated macrophages release several factors, 
including interleukin (IL)-6 and IL-10, which promote 
tumor cell growth, facilitate angiogenesis, and suppress 
the anti-tumor functions of other immune cells [24, 45]. 
Additionally, GSCs and tumor-associated macrophages 
interact with each other closely [46]. Tumor-associated 
macrophages secrete cytokines, such as pleiotrophin and 
TGF-β1, to maintain the stemness of GSCs and promote 
invasion of GSCs [24, 46, 47]. GSCs recruit monocyte-
derived macrophages from peripheral blood through par-
acrine periostin and osteopontin signaling [46, 58, 63]. 
GSCs also promote the survival of M2 tumor-supportive 
macrophages by secretion of WISP1, which play immune 
suppressive roles in the tumor microenvironment, [52]. 
The crosstalk between GSCs and macrophages has been 
explored actively, but the biological roles of DGCs in 
GBM progression, especially in the tumor microenviron-
ment, are largely unknown.
Here, using DGC-specific transcriptomic signatures, 
we investigated the biological roles of DGCs in the tumor 
microenvironment, and demonstrate that DGCs accel-
erate GSCs-dependent tumor progression by shaping a 




A deposited RNA sequencing dataset from three matched 
pairs (MGG4, 6, and 8) of GSCs and DGCs (GSE54791) 
[51] and single cell RNA-sequencing dataset from four 
GBM tumors (GSE84465) [16] were downloaded from 
the NCBI Gene Expression Omnibus (GEO) database. 
The deposited single cell RNA-sequencing dataset for 
two-dimensional representation of cellular states are 
available through the Broad Institute Single-Cell Por-
tal (https ://porta ls.broad insti tute.org/singl e_cell/study /
SCP39 3/singl e-cell-rna-seq-of-adult -and-pedia tric-gliob 
lasto ma) and NCBI GEO GSE131928 [34]. The gene 
expression data and metadata of The Cancer Genome 
Atlas (TCGA) GBM (HG-UG133A) and Ivy Glioblastoma 
Atlas Project (IVY GAP) were downloaded from GlioVis 
(http://gliov is.bioin fo.cnio.es) [8] or cBioPortal (http://
www.cbiop ortal .org) [10]. The stromal, immune, and 
tumor purity score of each patient was downloaded from 
ESTIMATE (http://bioin forma tics.mdand erson .org/
estim ate/) [60].
Bioinformatic analysis
Unsupervised hierarchical clustering of TCGA GBMs 
(HG-UG133A) with the DGC signature was performed 
by Morpheus (https ://softw are.broad insti tute.org/
morph eus). Single sample gene-set enrichment analysis 
(ssGSEA) scores were calculated using the single sample 
Gene Set Enrichment Analysis Projection (ssGSEAPro-
jection) module in GenePattern (https ://cloud .genep 
atter n.org) [2]. Gene set enrichment analysis (GSEA) was 
performed using the GSEA desktop application (http://
infiltration. This study provides new insight into the complex GBM microenvironment consisting of heterogeneous 
cells.
Keywords: Differentiated glioblastoma cell, Glioblastoma stem cell, CCN1, YAP/TAZ, TEAD, Mesenchymal subtype, 
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softw are.broad insti tute.org/gsea/downl oads.jsp) [50]. 
To identify specific immune cells linked to DGC sig-
natures or CCN1 in GBM, we examined TCGA GBM 
(HG-UG133A) dataset for 20 types of immune cells 
using validated gene set signatures [7, 20]. Gene ontol-
ogy enrichment analysis (GOEA) was performed through 
the GlioVis portal. To identify DGC-specific enhancer 
regions, deposited H3K27ac ChIP-sequencing data from 
three matched pairs (MGG4, 6, and 8) of GSCs and DGCs 
(GSE54047) [51] were downloaded from the NCBI Gene 
Expression Omnibus (GEO) database. DGC-specific 
enhancer regions were defined by selecting all enhanc-
ers present in DGCs, but absent in GSCs using BEDTools 
[42]. The H3K27ac signals in a 10 kb region of each site 
were visualized as heatmaps and metaplots using the 
plotHeatmap and plotProfile functions of deepTools 
[43]. For de novo and known motif enrichment analysis 
of DGC-specific enhancers, we used the HOMER soft-
ware package [26]. H3K27ac ChIP-sequencing enrich-
ment plots at the CCN1 locus of three matched GSC and 
DGC pairs (GSE54047) were visualized using Integrative 
Genomics Viewer [44].
Cell culture
The human GBM cell lines were U87ΔEGFR and 
U251MG provided by Dr. Balveen Kaur (University of 
Texas Health Science Center, Houston, TX). U87MG 
cells were purchased from the American Type Culture 
Collection. A172 and LNZ308 cells were provided by 
Dr. E. Antonio Chiocca (Brigham and Women’s Hospi-
tal, Boston, MA). Patient-derived GBM primary cultures 
MGG4, MGG8, MGG18, and MGG23 were provided by 
Dr. Hiroaki Wakimoto (Massachusetts General Hospital, 
Boston, MA). Normal human astrocytes (NHAs) were 
purchased from Lonza. U937 monocyte-like cells were 
purchased from the Japanese Cancer Research Resources 
Bank. Human embryonic kidney (HEK) 293FT cells were 
purchased from Thermo Fisher Scientific.
All DGCs, and U251MG, U87MG, U87ΔEGFR, A172, 
LNZ308, and HEK 293FT cells were cultured in Dul-
becco’s modified Eagle’s medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS), 100 U/ml penicil-
lin, and 100  µg/ml streptomycin. All GSCs were cul-
tured in neurobasal medium (Gibco) supplemented with 
0.5 × N2 supplement, 1 × B27 supplement minus vitamin 
A (Gibco), 0.5 × penicillin/streptomycin/amphotericin 
B suspension (FUJIFILM Wako), 3  mM L-glutamine 
(Gibco), 2  μg/ml heparin (Sigma-Aldrich), 20  ng/mL 
human EGF (PeproTech), and 20  ng/mL human FGF 
basic (PeproTech). U937 monocyte-like cells were cul-
tured in RPMI 1640 medium supplemented with 10% 
FBS, 100 U/ml penicillin, and 100  µg/ml streptomy-
cin. NHAs were cultured in AGM BulletKit (Lonza) in 
accordance with the manufacturer’s instructions. All cells 
were maintained at 37 °C and 5%  CO2, and confirmed to 
be free of mycoplasma. Cell lines were authenticated by 
Promega using short tandem repeat profiling in Decem-
ber 2016.
Isolation of GSCs and DGCs by fluorescence‑activated cell 
sorting
MGG4 and MGG8 cells were washed with PBS, blocked 
with anti-CD16/32 antibodies and normal mouse serum 
in PBS for 30 min at 4 °C, and then labeled with a Brilliant 
Violet 421 anti-human CD133 Antibody (BioLegend, 
#372808). Then, the cells were incubated with propid-
ium iodide, and CD133-positive and -negative cells were 
sorted by a BD FACSAria III Cell Sorter (Becton Dickin-
son). A Brilliant Violet 421 Mouse IgG1, κ Isotype Ctrl 
Antibody (BioLegend, #400158) was used as a negative 
control to determine the amount non-specific back-
ground staining. The sorted CD133-positive cells were 
cultured in the GSC medium described above. Matched 
CD133-negative cells were maintained in DMEM sup-
plemented with 10% FBS to maintain their differentiation 
status. GSC phenotypes were validated by expression of 
stem cell marker SOX2, their self-renewal capacity (serial 
neurosphere passaging, in  vitro limiting dilution assay), 
serum-induced cell differentiation, and tumor propaga-
tion capacity (in vivo limiting dilution).
DNA constructs and lentiviral transduction
Lentiviral vectors (LVs) expressing GFP (LV-GFP, 
Addgene, #26001) or RFP (LV-RFP, Addgene, #25999) 
were purchased from Addgene. For knockdown experi-
ments, two non-overlapping shRNAs against human 
CCN1 and TAZ were cloned into pLKO.1 puro (Addgene, 
#8453). A non-targeting scramble shRNA (#1864, 
shCONT) and two non-overlapping shRNAs against 
human YAP (#42540 and #42541) were purchased from 
Addgene. The target sequences of shRNAs used in this 
study were as follows. shCCN1-1: CGA ACC AGT CAG 
GTT TAC TTA; shCCN1-2 [targeting 3ʹ-untranslated 
regions (UTRs)]: GGC AGC TAT CTG CAC TCT AAA; 
shTAZ-1: GCG ATG AAT CAG CCT CTG AAT; shTAZ-
2: GCG TTC TTG TGA CAG ATT ATA, shYAP-1: GCC 
ACC AAG CTA GAT AAA GAA; shYAP-2: CCC AGT TAA 
ATG TTC ACC AAT; shCONT: CCT AAG GTT AAG TCG 
CCC TCG. Lentiviral constructs overexpressing wildtype 
CCN1 (pTomo-CCN1) or TAZ (pTomo-TAZ) were gen-
erated by cloning human CCN1 or TAZ open reading 
frames, respectively, into the pTomo vector (Addgene, 
#26291). Site-directed mutagenesis was performed to 
produce lentiviral constructs expressing D125A, a CCN1 
mutant defective for binding αvβ3/αvβ5 integrins, and 
DM, a CCN1 mutant defective for binding αMβ2/α6β1 
Page 4 of 23Uneda et al. acta neuropathol commun            (2021) 9:29 
integrins [14, 32]. A control lentiviral construct was gen-
erated by cloning multiple cloning sites into the pTomo 
vector. For YAP overexpression, FUW-tetO-wtYAP 
(Addgene, #84009) and FUdeltaGW-rtTA (Addgene, 
#19780) were used. For the negative control, FUW-tetO-
EGFP (Addgene, #84041) and FUdeltaGW-rtTA were 
used. HEK 293FT cells were used to generate lentiviral 
particles by cotransfection of packaging vectors psPAX2 
(Addgene, #12260) and pMD2.G (Addgene, #12259) with 
TransIT-LT1 (Mirus Bio). For lentiviral transduction, 
cells were transduced with lentiviruses for 48 h and then 
processed for analyses.
Mouse intracranial tumor models
All animal experiments were performed with approval 
from the Committee on the Ethics of Animal Experi-
mentation at Okayama University. For intracranial 
tumor xenograft models, female BALB/c-nu/nu mice 
(5–6  weeks old) were purchased from CLEA Japan Inc. 
The intracranial tumor xenograft models in mice were 
established as we described previously [28]. Briefly, the 
mice were anesthetized and tumor cells were stereotac-
tically injected into the right frontal lobe (3  mm lateral 
and 1  mm anterior from the bregma and 3  mm depth 
from the dura) using a stereotactic frame (Narishige) and 
Hamilton syringe (Hamilton). A mouse de novo GBM 
model was generated by stereotactic injection of lenti-
viruses harboring H-Ras and shP53 [pTomo-HrasV12-
IRES-GFP-shp53, the vector plasmid was a kind gift from 
Dr. Dinorah Friedmann-Morvinski (Tel Aviv Univer-
sity, Tel Aviv, Israel] into the hippocampus of transgenic 
mice expressing GFAP-Cre, FVB-Tg (GFAP-cre) 25Mes/J 
(The Jackson Laboratory, #004600) [21]. Mice with neu-
rological deficits or a moribund appearance including a 
hunched posture, gait changes, lethargy, and weigh loss 
were sacrificed. Following transcardial perfusion with 4% 
paraformaldehyde (PFA), brains were harvested, fixed 
in 4% PFA, and embedded in paraffin or cryopreserved 
in 30% sucrose for cryosectioning. To observe the effect 
of macrophage infiltration induced by CCN1, we used 
U87ΔEGFR, which has rapid tumorigenesis, in a prelimi-
nary experiment for the experiment using the GSC-DGC 
pair.
Human GBM tissue samples
Fresh GBM tumor tissue for qRT-PCR and immuno-
fluorescence staining were obtained from primary GBM 
patients who underwent surgical resection at Okayama 
University Hospital. The study was approved by the 
ethical committee of the Okayama University Gradu-
ate School of Medicine, Dentistry and Pharmaceutical 
Sciences, Okayama, Japan (approval no. 1608-026). All 
patients included in the study had provided informed 
written consent.
Immunofluorescence staining
Tumor samples from GBM patients and mouse intrac-
ranial GBM models were fixed in 4% paraformaldehyde 
overnight at 4  °C, followed by overnight cryoprotec-
tion with 30% sucrose in PBS at 4 °C. Samples were then 
sectioned at a thickness of 7 µm. Sections were washed 
with PBS twice, permeabilized, and then blocked with 
0.3% Triton X-100, 5% BSA in PBS for 1  h. Then, the 
sections were stained with primary antibodies against 
Iba1 (1  µg/mL, FUJIFILM Wako, #019-19741), CD206/
MMR (2 µg/mL, R&D Systems, #AF2535), SOX2 (2 µg/
mL, R&D Systems, #AF2018), and CCN1/Cyr61 (10 µg/
mL, Novus, #NB100-356) overnight at 4 °C, followed by 
the secondary antibodies against rabbit or goat immuno-
globulin G (IgG) labeled with Alexa Fluor dyes (Thermo 
Fisher Scientific) at room temperature for 1  h. After 
immunostaining, the samples were mounted with DAPI 
Fluoromount-G (SouthernBiotech, #0100-20). Images 
were obtained under an LSM780 confocal laser scanning 
microscope (Carl Zeiss).
TEAD luciferase reporter assay
For the TEAD luciferase reporter assay, 1 × 105 DGCs 
or GSCs were seeded in each well of a 24-well plate. 
After 12  h, the cells were transfected with the YAP/
TAZ-responsive TEAD Firefly luciferase reporter vector 
8 × GTIIC-luciferase (Addgene, #34615) (150  ng/cm2) 
and Renilla luciferase control reporter vector pGL4.74 
[hRluc/TK] (Promega) (100  ng/cm2) using TransIT-
LT1 (Mirus Bio) in accordance with the manufacturer’s 
instructions. At 24 h after transfection, Firefly and Renilla 
luciferase activities were quantified using the Dual-Lucif-
erase Reporter Assay System (Promega) in accordance 
with the manufacturer’s instructions.
Enzyme‑linked immunosorbent assay
Secreted CCN1 protein levels in conditioned media 
from paired GSCs and DGCs were quantified using an 
enzyme-linked immunosorbent assay (ELISA). DGCs or 
GSCs (1 × 106) were seeded in each well of a 12-well plate 
in DMEM supplemented with 10% FBS or GSC medium, 
respectively. After 12 h, the media were changed to fresh 
DMEM without FBS or fresh GSC medium and the cells 
were cultured for 24  h. At the end point, conditioned 
media were collected and analyzed using a Human 
Cyr61/CCN1 ELISA kit (RayBiotech, #ELH-CYR61) in 
accordance with the manufacturer’s instructions.
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Conditioned medium preparation
Conditioned media (CM) were obtained by culturing 
GSCs or DGCs at 2 × 106 cells/mL in RPMI 1640 medium 
without serum for 24 h. The cells were removed by cen-
trifugation at 2000  rpm at 4  °C for 10 min and the CM 
was sterile filtered through a 0.22-μm filter.
Migration assay
U937 cells were cultured in RPMI 1640 medium with 
10% FBS for 24 h before priming. U937 cells were primed 
with 5  nM phorbol 12-myristate 13-acetate (Promega, 
#V1171) for 48 h to become monocyte-derived unpolar-
ized macrophages. Migration assays were performed in 
24-well plated with ThinCert cell culture inserts (8-μm 
pores, Greiner Bio-One) in accordance with the manu-
facturer’s instructions. Briefly, 5 × 105 primed U937 
unpolarized macrophages suspended in serum-free cul-
ture medium were seeded in the upper chamber. Medium 
with recombinant human CCN1 protein (PeproTech, 
#120-25) or CM was added to the remaining receiver 
wells. Cells were then allowed to migrate for 48 h before 
fixation for staining with 0.05% crystal violet (FUJIFILM 
Wako, #031-04852).
Western blot analysis
Cells were collected and then lysed in cell lysis buffer 
(20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 
1  mM  Na2EGTA, and 0.5% Triton X-100) containing a 
cOmplete Protease Inhibitor Cocktail (Sigma-Aldrich) 
and PhosSTOP phosphatase inhibitor cocktail (Sigma-
Aldrich). After sonication, lysates were centrifuged at 
15,000 rpm at 4 °C, for 10 min. The protein concentration 
of the supernatants was measured using a bicinchoninic 
acid protein assay (Thermo Fisher Scientific). The super-
natants were added to a 1/3 volume of 4 × SDS sample 
buffer (240 mM Tris–HCl, pH 6.8, 8% SDS, 40% glycerol, 
0.1% bromophenol blue, and 20% 2-mercaptoethanol) 
and boiled at 95 °C for 5 min. Equal amounts of protein 
samples were applied to SDS-PAGE and then transferred 
to a PVDF membrane (Immobilon-P, 0.45  μm) (Mil-
liporeSigma). The membrane was blocked with 0.5% dry 
skim milk in TBST. After blocking, the membranes were 
incubated with primary antibodies overnight at 4 °C and 
then with secondary antibodies for 1 h at room temper-
ature. The signals were developed with Clarity Western 
ECL Substrate (Bio-Rad Laboratories) and detected with 
a ChemiDoc imaging system (Bio-Rad Laboratories). 
The primary antibodies were anti-CCN1/CYR61(1:1000, 
Cell Signaling Technology, #14479), anti-YAP (1:1000, 
Santa Cruz Biotechnology, #sc-101199), anti-TAZ/
WWTR1(1:1000, Sigma-Aldrich, #HPA007415), 
anti-SOX2 ((2  µg/mL, R&D Systems, #AF2018), and 
anti-GAPDH (1:1000, Sigma-Aldrich, #MAB374). The 
secondary antibodies were horseradish peroxidase-con-
jugated anti-mouse IgG (1:4,000, Cell Signaling Tech-
nology, #7076), anti-rabbit IgG (1:4,000, Cell Signaling 
Technology, #7074), and anti-goat IgG (1:4,000, Sigma-
Aldrich, #A5420).
Quantitative RT‑PCR
Trizol reagent (Invitrogen) was used to isolate total cel-
lular RNA from cell pellets. After digestion of genomic 
DNA using Recombinant DNase I (Takara Bio Inc.), a 
PrimeScript RT reagent Kit (Takara Bio Inc.) was used 
for reverse transcription into cDNA. Quantitative real-
time PCR was performed with a Rotor-Gene Q (QIA-
GEN) using Luna Universal qPCR Master Mix (New 
England Biolabs). qPCR primers used in this study were 
as follows. human CCN1 forward 5ʹ-CCT TGT GGA CAG 
CCA GTG TA-3ʹ and reverse 5ʹ-ACT TGG GCC GGT ATT 
TCT TC-3ʹ; human YAP forward 5ʹ-TAG CCC TGC GTA 
GCC AGT TA-3ʹ and reverse 5ʹ-TCA TGC TTA GTC CAC 
TGT CTGT-3ʹ; human TAZ forward 5ʹ-TCC CAG CCA 
AAT CTC GTG ATG-3ʹ and reverse 5ʹ-AGC GCA TTG 
GGC ATA CTC AT-3ʹ; 18S RNA forward 5ʹ-GTA ACC 
CGT TGA ACC CCA TT-3ʹ and reverse 5ʹ-CCA TCC AAT 
CGG TAG TAG CG-3ʹ.
Statistical analysis
GraphPad Prism 8 software was used to conduct statisti-
cal analysis of all data. Data are represented as the mean 
and SEM. Kaplan–Meier survival curves were generated 
using GraphPad Prism 8 software and the log-rank test 
was performed to assess statistical significances between 
groups. The Student’s t-test was used for comparisons 
between two groups. Comparisons between multiple 
groups were performed with one-way ANOVA with 
Tukey’s multiple comparisons test. Pearson’s correla-
tion test was used to measure the strength of the asso-
ciation between two variables. The chi-squared test was 
performed to examine differences between categorical 
variables. P values were designated as *P < 0.05, **P < 0.01 
***P < 0.001, ****P < 0.0001, and ns non-significant 
(P > 0.05).
Results
Determination of DGC‑specific transcriptomic signatures
To investigate transcriptomic profiles of DGCs compared 
with GSCs, we analyzed a deposited RNA sequencing 
dataset from three matched pairs of GSCs and DGCs [51] 
and extracted the top 50 genes that were differentially 
expressed between DGCs and GSCs (DGC and GSC sig-
nature genes) on the basis of the ranking metric score 
(signal-to-noise ratio) (Fig. 1a–c, Additional file 1: S1a,b).
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Validation of DGC‑specific transcriptomic signatures 
in single cell RNA‑sequencing data
Next, to confirm the presence of cell subpopulations 
emulated by in  vitro DGC and GSC culture models 
within a primary tumor, we evaluated the DGC and GSC 
signatures in the deposited single cell RNA-sequencing 
dataset from four GBM tumors [16]. GBM cells aligned 
with differentiation and stemness gradients in each 
tumor (Fig. 1d). Negative correlations between DGC and 
GSC signature single sample gene set enrichment analy-
sis (ssGSEA) scores [2] were also confirmed in the single 
cell RNA-sequencing data (Fig. 1e), which was consistent 
with the findings observed in the RNA sequencing data-
set of in  vitro culture models. A recent study has dem-
onstrated that malignant cells in GBM exist in four main 
cellular states that recapitulate neural-progenitor-like 
(NPC-like), oligodendrocyte-progenitor-like (OPC-like), 
astrocyte-like (AC-like), and mesenchymal-like (MES-
like) states [34]. Thus, we assessed the expression of DGC 
and GSC signature genes across the four GBM cellular 
states. The results showed that DGCs were enriched in 
the MES-like state, while GSCs were enriched in OPC-, 
NPC-, and AC-like states (Fig.  1f ). Gene set enrich-
ment analysis (GSEA) [50] of the in vitro culture models 
showed significant enrichment of the mesenchymal gene 
set in DGCs and the proneural gene set in GSCs (Fig. 1g). 
These results suggest that GBM tumors contain cell 
subpopulations modeled by the GSC and DGC culture 
models.
Validation of DGC‑specific transcriptomic signatures 
in larger tumor cohorts
To determine the validity of the DGC and GSC transcrip-
tomic signatures in larger tumor cohorts, we examined 
The Cancer Genome Atlas (TCGA) GBM dataset (HG-
UG133A), which contains data from 528 GBMs (Fig. 2a), 
and the Ivy Glioblastoma Atlas Project (IVY GAP) 
database, that contains 122 RNA sample data from 10 
patients (Fig. 2b). We performed unsupervised clustering 
of TCGA GBM dataset with the DGC signature to gen-
erate three groups: DGC-high (n = 177), DGC-medium 
(n = 163), and DGC-low (n = 188) (Fig.  2a). To assess 
the robustness of our clustering, we calculated ssGSEA 
scores [2] of the DGC and GSC signatures for individual 
GBM samples. The ssGSEA scores of the DGC signature 
were highly enriched in the DGC-high group compared 
with the DGC-low group (Fig. 2c). However, the ssGSEA 
scores of the GSC signature were highly enriched in the 
DGC-low group compared with the DGC-high group 
(Fig.  2d). The negative correlation between DGC and 
GSC signatures was confirmed in TCGA GBM and 
IVY GAP datasets (Fig.  2e). These results suggested the 
validity of the application of DGC signatures to clinical 
cohorts and our clustering shown in Fig. 2a.
Transcriptomic DGC signatures correlate 
with the mesenchymal subtype and poor patient 
prognoses
We next investigated the clinical and anatomical rel-
evances of the DGC signature in GBM cohorts. Ana-
tomically, regions of microvascular proliferation and 
pseudopalisading cells expressed the DGC signature 
more in GBM tissues, whereas the leading edge and infil-
trating tumor regions expressed the GSC signature more 
(Fig.  2b, f, Additional file  1: S2a). Consistent with the 
findings shown in Fig. 1g, the DGC signature was associ-
ated with the mesenchymal subtype in TCGA GBM and 
IVY GAP datasets (Fig.  2g, Additional file  1: S2b). Fur-
thermore, patients with higher expression of the DGC 
Fig. 1 Determination of DGC-specific transcriptomic signatures and their validation in single cell RNA-sequencing data. a Dot plot showing the 
ranking metric score (signal-to-noise ratio) of DGCs versus GSCs. Red and blue dots indicate the top 50 significantly altered genes in DGCs and 
GDCs. On the x axis, genes farther to the left have higher expression in DGCs, whereas genes farther to the right have higher expression in GSCs. 
NCBI Gene Expression Omnibus GSE54791. b Volcano plot comparing gene expression between DGCs and GSCs. Each dot represents one gene. 
Red and blue dots indicate the top 50 significantly altered genes in DGCs and GDCs. Genes were considered to be significantly different when the 
adjusted P value was < 0.05 and the difference of the mean fold change was > 2. NCBI Gene Expression Omnibus GSE54791. c Heat map of the top 
50 genes exclusively upregulated in DGCs and GSCs. NCBI Gene Expression Omnibus GSE54791. d Heat map shows expression of DGC and GSC 
signature ssGSEA scores and genes of each signature (rows) in individual GBM cells (columns) of single cell RNA-sequencing data from four GBM 
tumors (BT S1, BT S2, BT S4, and BT S6). Cells were grouped by the tumor and ordered by the DGC signature ssGSEA score. NCBI Gene Expression 
Omnibus GSE84465. e Correlation analysis between DGC and GSC signature ssGSEA scores in single cell RNA-sequencing data from four GBM 
tumors (BT S1, BT S2, BT S4, and BT S6). Pearson’s correlation test. NCBI Gene Expression Omnibus GSE84465. f Expression of DGC signature genes 
(left) and GSC signature genes (right) in a cluster of two-dimensional representation of cellular states. Each quadrant corresponds to one cellular 
state, the exact positions of malignant cells (dots) reflect their relative scores for the meta-modules, and their colors reflect gene expression levels. 
AC, astrocyte, MES, mesenchymal, OPC, oligodendrocyte-progenitor-cell, NPC, neural-progenitor-cell, TPM, transcripts per million. Source data are 
available through the Broad Institute Single-Cell Portal. (https ://porta ls.broad insti tute.org/singl e_cell/study /SCP39 3/singl e-cell-rna-seq-of-adult 
-and-pedia tric-gliob lasto ma) and NCBI Gene Expression Omnibus GSE131928. g GSEA analysis of mesenchymal and proneural subtypes of DGCs 
compared with GSCs. NCBI Gene Expression Omnibus GSE54791. NES: normalized enrichment score. FDR: false discovery rate
(See figure on next page.)
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signature exhibited poorer survival when grouped by 
both the clustering shown in Fig.  2a and ssGSEA score 
(Fig. 2h, Additional file 1: S2c). These results suggest that 
transcriptomic DGC signatures correlate with the mes-
enchymal subtype and poor patient prognoses.
Transcriptomic DGC signatures are associated 
with immune responses and macrophage signatures
To investigate the biological role of DGCs in GBM, we 
explored signaling pathways correlated with DGCs by 
GSEA using transcriptomic data of the in  vitro models 
(matched pairs of GSCs and DGCs) and TCGA GBM 
cohorts (Fig. 3a, b). GSEA of hallmark gene sets revealed 
prominent representation of immune response gene sets 
in the in vitro DGC models and DGC-high GBM, includ-
ing the interferon α/γ response, TNF α/NF-κB signaling, 
inflammatory response, interleukin-2 (IL-2)/STAT5 sign-
aling, and IL-6/STAT3 signaling (Fig.  3a, b, Additional 
file 1: S3a).
Next, to predict the presence of stromal/immune cell 
populations in tumors and tumor purity, we used the 
ESTIMATE method [60]. Using TCGA GBM dataset, 
we found that the DGC-high GBM group, which was 
enriched in the mesenchymal subtype (Fig.  2g), exhib-
ited high stromal and immune signatures and low tumor 
purity (Fig.  3c, d, Additional file  1: S3b). These results 
were consistent with previous findings of an increased 
presence of stromal and immune cells in mesenchymal 
type GBM [56].
To identify specific immune cells linked to DGC sig-
natures, we examined TCGA GBM dataset for various 
types of immune cells using validated gene set signatures 
[7, 20]. Analysis of immune cell signatures demonstrated 
that high DGC-signature expression correlated with 
significant enrichment of macrophages (total, M1, and 
M2-macrophages), microglia, and monocytes (Fig.  3e). 
Therefore, we assessed macrophage-related gene sets 
(macrophage chemoattractant, migration, and activa-
tion) by GSEA and found that the DGC-high GBM 
group exhibited significant enrichment of these gene sets 
(Fig. 3f ). Taken together, these in silico findings suggest a 
role of DGCs in macrophage infiltration into GBM.
DGCs promote macrophage infiltration and tumor 
progression in cooperation with GSCs
To perform matched GSC and DGC experiments, we 
adopted an established protocol to isolate GSCs and 
DGCs. GBM tumor cells were isolated by fluores-
cence-activated cell sorting on the basis of CD133, a 
stem-cell marker [1, 51, 57]. The CD133-positive cells 
were cultured as GSCs in serum-free stem cell medium 
and CD133-negative cells were cultured as DGCs in 
serum-containing differentiation medium (Fig.  4a). 
GSCs grew as spheres under serum-free conditions 
and DGCs expanded as adherent monolayers under 
serum-containing conditions (Fig. 4b). Consistent with 
the in silico findings in Fig.  3, conditioned medium 
(CM) of DGCs isolated from patient-derived GBM 
cells (MGG4 and MGG8) and human GBM cell line 
U87ΔEGFR exhibited an increase in U937 macrophage 
migration relative to the control medium in transwell 
migration assays (Fig.  4c, Additional file  1: S4a). To 
confirm the contribution of DGCs to tumor progres-
sion, we implanted GSCs alone, matched DGCs alone, 
or their combination derived from MGG8 cells into the 
brains of immunocompromised mice. We determined 
the ratio of DGCs and GSCs by referring to a previous 
study [57]. As reported in previous studies [51, 57], 
coimplantation of DGCs and GSCs reduced the sur-
vival of tumor xenograft-bearing mice compared with 
(See figure on next page.)
Fig. 2 Validation of DGC-specific transcriptomic signatures in larger tumor cohorts and their correlation with the mesenchymal subtype and a poor 
patient prognosis. a Hierarchical clustering of human TCGA GBM samples (HG-UG133A, n = 528) into DGC-high (n = 177), DGC-medium (n = 163), 
and DGC-low (n = 188) groups using DGC signature genes. The corresponding DGC signature groups for each sample determined via hierarchical 
clustering are labeled (top). Heat map showing Z-scores of DGC and GSC signatures determined by single sample gene set enrichment analysis 
(ssGSEA) of individual GBM samples (second and third from top). The corresponding GBM subtype for each sample is labeled (fourth from top). b 
Heat map shows expression the DGC and GSC signature ssGSEA scores (top and second from top) and genes of each signature (rows) for each RNA 
sample in the anatomic structure study dataset (122 RNA sample data from 10 patients) from the IVY GAP database (columns). The corresponding 
GBM subtype and histology for each sample is are (bottom and second from bottom). c ssGSEA scores of DGC signature genes of DGC-high 
(n = 177), DGC-medium (n = 163), and DGC-low (n = 188) patients in TCGA GBM dataset (HG-UG133A, n = 528). Violin plots represent the median 
(thick dotted line) and quartiles (dotted line). ****P < 0.0001, one-way ANOVA with Tukey’s multiple comparisons test. d ssGSEA scores of the GSC 
signature genes of three DGC groups in TCGA GBM dataset (HG-UG133A, n = 528). Violin plots represent the median (thick dotted line) and quartiles 
(dotted line). **P < 0.01, ****P < 0.0001, one-way ANOVA with Tukey’s multiple comparisons test. e Correlation analysis between DGC and GSC 
ssGSEA scores in TCGA GBM dataset (HG-UG133A, n = 528) and IVY GAP dataset (122 RNA sample data from 10 patients). Pearson’s correlation test. f 
ssGSEA scores of the DGC signature genes in multiple regions of the IVY GAP data (122 RNA sample data from 10 patients). Violin plots represent the 
median (thick dotted line) and quartiles (dotted line). **P < 0.01, ****P < 0.0001, one-way ANOVA with Tukey’s multiple comparisons test. g Molecular 
subtype distribution among DGC signature groups in TCGA GBM dataset (HG-UG133A, n = 528). ****P < 0.0001, chi-squared test. h Kaplan–Meier 
analyses between patients in DGC-high and DGC-low groups of TCGA GBM dataset (HG-UG133A). Log-rank P value analyses
Page 9 of 23Uneda et al. acta neuropathol commun            (2021) 9:29  
GSCs alone, whereas as many as 1 × 105 DGCs alone 
did not initiate a tumor (Fig.  4d). Hematoxylin and 
eosin (H&E) staining of whole brain sections showed 
increases in the tumor size and cell density with 
coimplantation of GSCs and DGCs (Fig.  4e). Further-
more, coimplantation of DGCs and GSCs increased 
infiltration of CD206-positive tumor-supportive mac-
rophages (M2 macrophages) compared with GSCs 
alone (Fig. 4f–h). Finally, to confirm successful implan-
tation of DGCs into the brains of recipient mice only 
when cotransplanted with GSCs, we adopted trac-
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fluorescent proteins (Additional file  1: Fig. S4b). To 
this end, GSCs and DGCs were infected with lentiviral 
vectors (LVs) expressing GFP or RFP (Additional file 1: 
Fig. S4c). We implanted GSCs labeled with RFP alone, 
DGCs labeled with GFP alone, or their combination 
(Mixed) into the brains of recipient mice. DGCs were 
successfully engrafted in mouse brains when cotrans-
planted (Mixed) with GSCs, but transplantation of 
DGCs alone did not initiate a tumor (Additional file 1: 
Fig. S4d). Collectively, these results demonstrate that 
DGCs promote macrophage infiltration and tumor 
progression in cooperation with GSCs.
Identification of DGC‑specific transcriptional regulators
To identify DGC-specific enhancers, we compared the 
epigenetic landscape of three matched pairs (MGG4, 6, 
and 8) of GSCs and DGCs by analysis of H3K27ac ChIP-
sequencing data (Fig.  5a, b) [51]. DGC-specific enhanc-
ers displayed enrichment for transcriptional motifs of 
TEA domain family member (TEAD) 1–4 and activator 
protein-1 (AP-1) (Fig.  5c, Additional file  1: S5a). AP-1 
is a dimer of JUN (JUN, JUNB, and JUND) and FOS 
(FOS, FOSB, FOSL1/FRA1, and FOSL2/FRA2) families 
of leucine-zipper proteins [18]. Transcriptional coac-
tivator with PDZ-binding motif (TAZ), also known by 
gene name WW domain-containing transcription regu-
lator 1 (WWTR1), and its paralog, Yes-associated pro-
tein (YAP), also known by gene name YAP1, are the two 
nuclear effectors of the Hippo signaling pathway. YAP/
TAZ/TEAD and AP-1 form a complex that synergisti-
cally activates YAP/TAZ target genes [62]. Indeed, TEAD 
transcriptional activity was regulated by YAP/TAZ 
(Additional file 1: Fig. S5b–e). Furthermore, DGCs exhib-
ited significant enrichment of YAP-related signatures 
(Fig. 5d) and upregulation of TEAD transcriptional activ-
ity (Fig.  5e) compared with GSCs. These findings were 
consistent with the results of motif enrichment analy-
sis. Collectively, these results demonstrated that DGCs 
exhibited a significant increase in YAP/TAZ/TEAD 
activity.
CCN1 is a potential protein secreted from DGCs to regulate 
macrophage recruitment
To identify the DGC signature genes that governed 
macrophage recruitment for further study, we selected 
17 genes encoding secreted proteins (The Human Pro-
tein Atlas [54]: https ://www.prote inatl as.org/human 
prote ome/tissu e/secre tome) from the 50 DGC signature 
genes (Fig.  5f ) because macrophages are recruited by 
secreted factors. Of these 17 genes, cellular communi-
cation network factor 1 (CCN1), also known as cysteine 
rich angiogenic inducer 61 (CYR61), was selected for 
validation and further analyses (Fig.  5f ) because it is 
a target gene of the YAP/TAZ/TEAD complex [40]. 
In fact, protein and mRNA levels of CCN1 were posi-
tively correlated to YAP (YAP1) and TAZ (WWTR1) 
in GBM cells and clinical samples from our institution 
and TCGA (Additional file  1: Fig. S5f–h). Expression 
of CCN1 was regulated by YAP/TAZ (Additional file 1: 
Fig. S5i–l).
To directly validate upregulation of CCN1 in DGCs, 
we examined the active enhancer landscape of CCN1 
across three matched pairs of GSCs and DGCs derived 
from GBM patients [51], which revealed markedly 
active CCN1 enhancers in DGCs as measured by 
H3K27ac peak levels (Fig.  5g). Next, we quantified 
the relative expression levels of CCN1 by qRT-PCR 
between DGCs and GSCs (MGG4 and MGG8), which 
demonstrated the increased expression levels of CCN1 
in DGCs (Fig.  5h). To confirm translation of these 
mRNAs into proteins, we measured CCN1 protein 
by the enzyme-linked immunosorbent assay (ELISA), 
which confirmed that DGCs secreted higher levels of 
CCN1 than GSCs (Fig.  5i). Furthermore, western blot-
ting showed increases in CCN1 and YAP/TAZ pro-
teins in DGCs compared with those in GSCs (Fig.  5j). 
Fig. 3 Transcriptomic DGC signatures are associated with immune responses and macrophage signatures. a Bar graph showing the normalized 
enrichment score (NES) of GSEA analysis of hallmark gene sets upregulated in DGCs compared with GSCs. Twenty-six gene sets were significantly 
enriched at a false discovery rate (FDR) of < 0.25 and nominal P value of < 0.05 in DGCs. NCBI Gene Expression Omnibus GSE54791. Red bars indicate 
signatures related to immune responses. b Bar graph showing the NES of GSEA analysis of hallmark gene sets upregulated in DGC-high GBMs 
(n = 177) compared with DGC-low GBMs (n = 188). Twenty-nine gene sets were significantly enriched at FDR < 0.25 and nominal P value < 0.05 
in DGC-high GBMs. TCGA GBM dataset (HG-UG133A, n = 528). Red bars indicate signatures related to immune responses. c Immune scores of 
DGC-high (n = 177), DGC-medium (n = 163), and DGC-low (n = 188) patients in TCGA GBM dataset (HG-UG133A, n = 528). Violin plots represent 
the median (thick dotted line) and quartiles (dotted line). ****P < 0.0001, one-way ANOVA with Tukey’s multiple comparisons test. d Stromal scores 
of DGC-high, -medium, and -low patients in TCGA GBM dataset (HG-UG133A). Violin plots represent the median (thick dotted line) and quartiles 
(dotted line). ****P < 0.0001, one-way ANOVA with Tukey’s multiple comparisons test. e GSEA analysis of various types of immune cell signatures 
upregulated in DGC-high (n = 177) compared with DGC-low (n = 188) patients in TCGA GBM dataset (HG-UG133A). Red bars indicate FDR < 0.25. 
f GSEA analysis of macrophage-related signatures upregulated in DGC-high (n = 177) compared with DGC-low (n = 188) patients in TCGA GBM 
dataset (HG-UG133A)
(See figure on next page.)
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To exclude the effects of cell culture conditions on the 
higher expression of CCN1 in DGCs, we performed 
dual immunofluorescence staining of GBM surgical 
specimens for CCN1 and GSC marker SOX2. In human 
GBM specimens, DGC-like cells (SOX2 negative and 
CCN1 positive) and GSC-like cells (SOX2 positive and 
CCN1 negative) were observed (Fig. 5k). Expression of 
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SOX2 and OLIG2 in clinical samples of TCGA (Fig. 5l). 
Taken together, these findings support that CCN1 as a 
potential protein secreted from DGCs, which governs 
macrophage recruitment.
DGCs augments macrophage infiltration into GBM 
through secretion of CCN1
To investigate the biological role of CCN1 in GBM, we 
explored transcriptomic data of TCGA GBM cohorts. 
CCN1-high GBMs exhibited prominent representation 
of immune response gene sets in GSEA, which included 
the interferon α/γ response, TNF-α/NF-κB signaling, 
inflammatory response, interleukin-2 (IL-2)/STAT5 sign-
aling, and IL-6/STAT3 signaling (Fig.  6a). CCN1-high 
GBMs exhibited higher stromal and immune signatures 
and lower tumor purity than CCN1-low GBMs (Fig. 6b, c, 
Additional file 1: S6a). Analysis of immune cell signatures 
demonstrated that high CCN1 expression correlated to 
significant enrichment of macrophages (total M1 and 
M2), microglia, and monocytes (Fig. 6d). Gene ontology 
enrichment analysis (GOEA) of the subontologies of the 
Biological Process in TCGA GBM patients, which dem-
onstrated that leukocyte migration and chemotaxis activ-
ity were CCN1-regulated processes (Additional file 1: Fig. 
S6b). Furthermore, the CCN1-high GBM group exhibited 
significant enrichment of macrophage-related gene sets 
(macrophage chemoattractant, migration, and activation) 
in the GSEA (Fig. 6e). Taken together, these in silico find-
ings suggest a role of CCN1 in macrophage infiltration 
into GBM.
Next, to determine the CCN1 distribution and its 
correlation with macrophage infiltration into GBMs, 
frozen sections of tumor tissue from a mouse de novo 
GBM model were coimmunostained with CCN1 and 
M2 macrophage marker CD206. We found that tumor 
areas with more CD206-positive macrophage infiltra-
tion showed more CCN1 staining (Additional file 1: Fig. 
S6c). To directly validate the capacity of CCN1 to func-
tion as a macrophage chemoattractant, we conducted 
transwell migration assays using U937 macrophages 
and found that recombinant CCN1 protein increased 
U937 macrophage migration (Fig. 6f ). To more strictly 
assess the effect of CCN1 on macrophage migration 
and tumor growth, we conducted conditional small 
hairpin RNA (shRNA)-mediated knockdown of CCN1 
using lentiviral vectors in DGCs from patient-derived 
GBM cells (MGG4 and MGG8 DGCs) and U87ΔEGFR 
cells (Additional file 1: Fig. S6d). Conditioned medium 
(CM) from DGCs (MGG4 and MGG8 DGCs) and 
U87ΔEGFR cells transduced with shRNA that tar-
geted CCN1 (shCCN1) decreased U937 macrophage 
migration relative to a non-targeting control shRNA 
(shCONT) in transwell migration assays (Fig. 6g, Addi-
tional file  1: S6e). Mice bearing xenografts formed by 
U87ΔEGFR cells transduced with shCONT exhibited 
more macrophage infiltration into tumors and shorter 
survival compared with those transduced with shCCN1 
(Additional file  1: Fig. S6f–i). Furthermore, to address 
the significance of CCN1 secreted from DGCs in the 
mouse xenograft model, we coimplanted GSCs and 
DGCs transduced with shCONT or shCCN1 into the 
brains of immunocompromised mice. The combination 
of GSCs and DGCs transduced with shCCN1 led to 
reductions in macrophage infiltration into tumors and 
the tumor size compared with the combination of GSCs 
and DGCs transduced with shCONT (Fig. 6h–k). Mice 
bearing xenografts formed by GSCs in combination 
with DGCs transduced with shCONT had shorter sur-
vival than those bearing xenografts formed by the com-
bination of GSCs and DGCs transduced with shCCN1 
(See figure on next page.)
Fig. 4 DGCs promote macrophage infiltration and tumor progression in cooperation with GSCs. a Flow cytometric analysis of CD133 in MGG8 cells. 
Sorted CD133 + cells were cultured as GSCs and CD133-cells were cultured as DGCs. b Representative images of paired GSCs and DGCs derived 
from two primary human GBM specimens (MGG4 and MGG8). Scale bar, 300 µm. c Representative image (left panel) and quantification (right panel) 
of transwell analysis of U937 macrophages upon stimulation with control medium or conditioned medium (CM) from DGCs (MGG4 and MGG8). 
Scale bar, 100 μm. n = 4 biological replicates, mean ± SEM, ***P < 0.001, Student’s t-test. d Kaplan–Meier (upper) and log-rank P value (bottom) 
analyses of mice bearing orthotopic xenografts of 1 × 103 glioma stem-like cells (GSCs) alone, 1 × 105 differentiated glioblastoma cells (DGCs) alone, 
or cotransplanted 1 × 104 DGCs with 1 × 103 GSCs derived from MGG8 cells. e Representative H&E stainings of tumor-bearing brains harvested at 
30 days after implantation of 1 × 103 GSCs alone, or 1 × 103 GSCs plus 1 × 104 matched DGCs derived from MGG8. Scale bars indicate 2000, 100 
and 50 µm in gross and detail views, respectively. Middle and right panels are high magnifications of the areas marked by rectangles in left panels. f 
Representative confocal images of tumor-bearing brains harvested at 30 days after implantation of 1 × 103 GSCs alone, or 1 × 103 GSCs plus 1 × 104 
matched DGCs derived from MGG8. Scale bar, 100 µm. Iba1 (red), CD206 (green), and DAPI (blue). g Quantitation of pan-macrophage  (Iba1+) 
and M2 macrophage  (CD206+) densities in xenografts formed by 1 × 103 GSCs alone or 1 × 103 GSCs plus 1 × 104 matched DGCs derived from 
MGG8 cells. The total number of macrophages was counted in five randomly selected fields per sample. n = 5 biological replicates, mean ± SEM, 
***P < 0.001, ****P < 0.0001, Student’s t-test. h Quantitation of the fraction of M2 macrophages  (CD206+). The fraction was determined by M2 
macrophages  (CD206+) among pan-macrophages  (Iba1+) in 1 × 103 GSCs alone or 1 × 103 GSCs plus 1 × 103 matched DGCs xenografts. The total 
number of macrophages was counted in five randomly selected fields per sample. n = 5 biological replicates. Data are represented as means ± SEM. 
**P < 0.01, Student’s t-test
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(Fig.  6l). Collectively, these results suggest that DGCs 
augment macrophage infiltration into tumors and 
tumor progression, at least in part, through secretion of 
CCN1.
CCN1 secreted from DGCs augments macrophage 
infiltration through integrins
CCN1 functions through binding to at least five differ-
ent integrins (αvβ3, αvβ5, α6β1, αIIbβ3, and αMβ2) [31]. 
The expression of these CCN1-binding integrins was 
positively correlated to DGC signature genes and CCN1 
in TCGA GBM (HG-U133A) dataset (Fig. 7a, Additional 
file  1: S7a). Furthermore, we calculated ssGSEA scores 
of the ITG signature (expression of CCN1-binding inte-
grins) for individual GBM samples. The ITG signature 
genes were also positively correlated to DGC signature 
genes and CCN1 (Fig. 7b). In the IVY GAP dataset, ITG 
signature genes were particularly enriched in regions of 
microvascular proliferation, while expression of ITG sig-
nature genes was lower in leading edge regions (Fig. 7c, 
d). Next, we investigated deposited single cell RNA-
sequencing data from GBM tumors and confirmed that 
CCN1 was expressed in neoplastic cells and CCN1-bind-
ing integrins were expressed in myeloid cells (Additional 
file 1: Fig. S7b).
To investigate whether DGC-derived CCN1-medi-
ated macrophage infiltration into GBM may be medi-
ated by integrins, we cloned lentiviral vectors harboring 
wildtype (WT) CCN1 or mutant CCN1 (D125A [14], a 
CCN1 mutant defective for binding αvβ3/αvβ5 integ-
rins, and DM [32], a CCN1 mutant defective for binding 
αMβ2/α6β1 integrins) (Fig. 7e). We found that rescue of 
endogenous CCN1, which was knocked down by shRNA 
that targeted 3ʹ-untranslated regions (UTRs), by exog-
enously transduced lentiviruses that harbored WT CCN1 
restored macrophage infiltration in  vitro and in  vivo, 
increased the tumor size, and reduced animal survival, 
but not the empty vector control or CCN1 mutants 
defective for integrin binding (Fig. 7g–k, Additional file 1: 
S7c–g).
To determine the clinical relevance of the DGC signa-
ture and CCN1-binding integrins in GBM patients, we 
re-examined TCGA GBM (HG-U133A) dataset. High 
expression of CCN1 and the ITG signature (expression 
of CCN1-binding integrins) was associated with a poor 
prognosis (Fig.  7l, m). Furthermore, expression of the 
DGC signature combined with CCN1 or the ITG-signa-
ture were negatively correlated to overall patient survival 
(Fig. 7n, o).
Taken together, our data elucidated the biological roles 
of DGCs, especially in the tumor microenvironment. 
DGCs augment macrophage infiltration through CCN1 
to promote tumor progression of GBM.
Discussion
In this study, we extracted DGC signature genes from 
transcriptomic profiles of matched pairs of in vitro GSCs 
and DGCs models. We evaluated the DGC signature 
genes in single cell RNA-sequencing data, which con-
firming the presence of cell subpopulations emulated 
by in  vitro culture models within a primary tumor. We 
found that the DGC gene signature was correlated to 
macrophage-related genes, the mesenchymal subtype 
signature, and poor survival. DGCs exhibited significant 
enrichment of YAP/TAZ/TEAD activity compared with 
Fig. 5 Identification of DGC-specific transcriptional regulators and a potential protein that governs macrophage recruitment by DGCs. a Heat map 
showing H3K27ac signals of all DGC-specific enhancers in three matched GSCs and DGCs (MGG4, MGG6, and MGG8). H3K27ac chip sequencing 
data were derived from NCBI Gene Expression Omnibus GSE54047. b Metaplot showing average H3K27ac signals of all DGC-specific enhancers 
in three matched GSCs and DGCs (MGG4, MGG6, and MGG8). H3K27ac chip sequencing data were derived from NCBI Gene Expression Omnibus 
GSE54047. c De novo and known motif enrichment analysis of DGC-specific enhancers defined in a, b displayed enrichment for transcriptional 
motifs of the TEAD transcription factor family. d GSEA analysis of YAP-related signatures upregulated in DGCs compared with GSCs. NCBI Gene 
Expression Omnibus GSE54791. NES: normalized enrichment score. FDR: false discovery rate. e Quantification of the TEAD luciferase reporter assay 
of matched pairs of GSCs and DGCs derived from MGG4 and MGG8 cells. Data are presented as the mean ± SEM of four independent experiments. 
*P < 0.05, ***P < 0.001. f Venn diagram showing the intersection between DGC signature genes (n = 50) and genes encoding secreted proteins from 
the human protein atlas (n = 1708). CCN1 was selected because it is a target gene of the YAP/TAZ-TEAD complex. g H3K27ac ChIP-sequencing 
enrichment plot at the CCN1 locus of three matched pairs of GSCs and DGCs (MGG4, MGG6, and MGG8). Matched pairs of GSC and DGC data were 
derived from NCBI Gene Expression Omnibus GSE54047. h qRT-PCR quantification of CCN1 mRNA levels in matched pairs of GSCs and DGCs derived 
from MGG4 and MGG8 cells. Data are presented as the mean ± SEM of two independent experiments. **P < 0.01, ***P < 0.001. i ELISA quantification 
of secreted CCN1 protein levels in conditioned media from paired GSCs and DGCs derived from MGG4 and MGG8 cells. Data are presented as 
the mean ± SEM of three independent experiments. **P < 0.01. j DGCs express elevated CCN1, YAP and TAZ protein levels relative to GSCs. Protein 
levels of CCN1, YAP, TAZ and SOX2 (GSC marker) were assessed by immunoblotting in two pairs of GSCs and DGCs of patient-derived glioma cell 
lines (MGG4 and MGG8). GAPDH was used as a loading control. k Immunofluorescence staining of SOX2 (green) and CCN1 (red) in frozen sections 
of human GBM specimens counterstained with DAPI (blue). Scale bar, 50 μm. Green arrowheads, SOX2-positive GSC-like cells. Red arrowheads, 
SOX2-negative DGC-like cells. Middle and right panels are high magnifications of the rectangle area in the left panel. l Correlation between CCN1, 
SOX2, and OLIG2 in TCGA GBM (HG-U133A) dataset. Red numbers indicate the correlation R-value. Pearson’s correlation test
(See figure on next page.)
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GSCs. We elucidated that DGCs promote macrophage 
recruitment into GBM tissue through secretion of CCN1.
The significance of GSCs is undeniable considering 
their capacity for self-renewal, differentiation, and tumor 
propagation in  vivo, and their contribution to thera-
peutic resistance, immune escape, and angiogenesis [1, 
23]. The focus on GSCs has overlooked the importance 
of differentiated progeny such as DGCs. A recent study 
has shown that DGCs also contribute to tumor progres-
sion in concert with GSCs through a paracrine loop [57]. 
However, the roles of DGCs in the tumor microenvi-
ronment of GBM remain obscure. In the present study, 
we focused on the significant correlation between DGC 
and macrophage signature genes, and established that 
DGCs secrete CCN1 to promote macrophage infiltra-
tion into the GBM tumor microenvironment. In addition 
to CCN1, CLCF1, a secreted protein included among 
the DGC signature genes, is implicated in macrophage 
activation [37]. Furthermore, a recent study of medul-
loblastoma models has also shown that tumor-derived 
astrocytes, differentiated progeny from tumor progeni-
tors, induce polarization of resident brain microglia 
towards protumorigenic macrophages by secreting IL-4 
[59]. These findings suggest that not only tumor progeni-
tors such as GSCs, but also differentiated progeny such 
as DGCs play an essential role in shaping the complex 
tumor immune microenvironment by promoting mac-
rophage infiltration.
The mesenchymal signature of GBM can be shaped by 
several factors such as stromal cells, accumulated muta-
tions in tumor cells, the cell of origin, anatomical loca-
tion/tumor microenvironments, and therapy-induced 
mesenchymal transition [4]. The presence of mac-
rophages/microglia is associated with the mesenchymal 
subtype of GBM [6, 34, 56]. Genetic deficiency of NF1 
attracts macrophages/microglia into tumors and a mac-
rophage/microglia-rich microenvironment also induces a 
mesenchymal tumor cell phenotype [56]. We found that 
DGCs themselves had a mesenchymal gene signature and 
the DGC signature was anatomically enriched in perine-
crotic/hypoxic (pseudopalisading) regions and microvas-
cular proliferative regions. These findings are consistent 
with prior reports indicating that the mesenchymal sig-
nature is enriched in perinecrotic/hypoxic regions and 
microvascular proliferative regions [41]. Thus, DGCs 
may induce a mesenchymal phenotype by attracting 
macrophages.
DGCs do not form tumors when implanted alone [51, 
57]. This suggest that retrograde dedifferentiation from 
DGCs to GSCs essentially cannot occur in a tumor [51]. 
DGCs successfully implant in brains of recipient mice 
only when cotransplanted with GSCs, which contrib-
ute to GSC-dependent tumor progression [57]. We also 
(See figure on next page.)
Fig. 6 DGCs augment macrophage infiltration through secretion of CCN1 in GBM. a Bar graph showing the normalized enrichment score (NES) 
of GSEA analysis of hallmark gene sets upregulated in CCN1-high GBMs (n = 264) compared with CCN1-low GBMs (n = 264). Thirty gene sets were 
significantly enriched at a false discovery rate (FDR) of < 0.25 and nominal P value of < 0.05 in CCN1-high GBMs. TCGA GBM dataset (HG-UG133A, 
n = 528). Red bars indicate signatures relate to immune responses. b Immune score of CCN1-high (n = 264) and CCN1-low (n = 264) GBMs in TCGA 
GBM dataset (HG-UG133A, n = 528). Violin plots represent the median (thick dotted line) and quartiles (dotted line). ****P < 0.0001, Student’s t-test. 
c Stromal score of CCN1-high and CCN1-low GBMs in TCGA GBM dataset (HG-UG133A). Violin plots represent the median (thick dotted line) and 
quartiles (dotted line). ****P < 0.0001, Student’s t-test. d GSEA analysis of various types of immune cell signatures upregulated in CCN1-high GBMs 
(n = 264) compared with CCN1-low GBMs (n = 264) in TCGA GBM dataset (HG-UG133A, n = 528). Red bars indicate FDR < 0.25. e GSEA analysis 
of macrophage-related signatures upregulated in CCN1-high GBMs (n = 264) compared with CCN1-low GBMs (n = 264) in TCGA GBM dataset 
(HG-UG133A, n = 528). FDR < 0.25 was defined as significantly enriched. f Representative image (upper panel) and quantification (lower panel) 
of transwell analysis of U937 macrophages upon stimulation with or without recombinant CCN1 (10 ng/ml). Scale bar, 100 μm. n = 4 biological 
replicates, mean ± SEM, ****P < 0.0001, Student’s t-test. CONT: control. g Representative image (upper panel) and quantification (lower panel) of 
transwell analysis of U937 macrophages upon stimulation with conditioned medium (CM) from DGCs (MGG4 and MGG8 DGCs) transduced with 
shCONT or shCCN1. Scale bar, 100 μm. n = 4 biological replicates, mean ± SEM, ****P < 0.0001, one-way ANOVA with Tukey’s multiple comparisons 
test. h Representative confocal images of tumor-bearing brains harvested at 30 days after implantation of 1 × 103 GSCs plus 1 × 104 matched DGCs 
transduced with shCONT or 1 × 103 GSCs plus 1 × 104 DGCs transduced with shCCN1 derived from MGG8. Scale bar, 100 µm. Iba1 (red), CD206 
(green), and DAPI (blue). i Quantitation of pan-macrophages  (Iba1+) and M2 macrophages  (CD206+) densities in xenografts formed by 1 × 103 
GSCs plus 1 × 104 matched DGCs transduced with shCONT or 1 × 103 GSCs plus 1 × 104 DGCs transduced with shCCN1 derived from MGG8 cells. 
The total number of macrophages was counted in five randomly selected fields per sample. n = 5 biological replicates, mean ± SEM, ****P < 0.0001, 
one-way ANOVA with Tukey’s multiple comparisons test. j Quantitation of the fraction of M2 macrophages  (CD206+). The fraction was determined 
by M2 macrophages  (CD206+) among pan-macrophages  (Iba1+) in xenografts formed by 1 × 103 GSCs plus 1 × 104 matched DGCs transduced 
with shCONT or 1 × 103 GSCs plus 1 × 104 DGCs transduced with shCCN1. The total number of macrophages was counted in five randomly selected 
fields per sample. n = 5 biological replicates. Data are represented as means ± SEM. **P < 0.01, ***P < 0.001, one-way ANOVA with Tukey’s multiple 
comparisons test. k Representative H&E stainings of tumor-bearing brains harvested at 30 days after implantation of 1 × 103 GSCs plus 1 × 104 
matched DGCs transduced with shCONT or 1 × 103 GSCs plus 1 × 104 DGCs transduced with shCCN1 derived from MGG8. Scale bars, 2000 µm. 
l Kaplan–Meier (left) and log-rank P value (right) analyses of mice bearing orthotopic xenografts of 1 × 103 GSCs plus 1 × 104 matched DGCs 
transduced with shCONT or 1 × 103 GSCs plus 1 × 104 DGCs transduced with shCCN1 derived from MGG8 cells
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obtained the same result in the present study. Consider-
ing our results that DGCs had a mesenchymal gene sig-
nature and GSCs had a proneural gene signature when 
compared each other, increased intratumoral heteroge-
neity at the earliest time of tumor initiation by cotrans-
plantation of DGCs and GSCs may accelerate tumor 
progression. This may be consistent with the result of a 
previous study in which proneural GBM patients with 
a high proportion of alternate subtype tumor cells had 
significantly worse outcomes compared with the pure 
proneural subtype [38]. Combination therapies that 
simultaneously target both DGCs and GSCs may be 
needed to overcome this intratumoral heterogeneity of 
GBMs.
In GBMs, TAZ is a transcriptional coactivator that 
drives the gene expression program of mesenchymal 
differentiation in a TEAD-dependent fashion [5]. We 
found that DGCs exhibited significant enrichment of 
YAP/TAZ/TEAD activity compared with GSCs. Previ-
ous studies have reported that serum stimulation in vitro 
activates AP-1, a transcriptional partner of TEADs, and 
YAP/TAZ [61, 62, 64]. Additionally, YAP/TAZ are impli-
cated in mechanotransduction. When cells are cultured 
on a stiff substrate, YAP/TAZ localize in the nucleus 
and become transcriptionally active [17]. Our results 
are reasonable considering the cell culture conditions 
under which GSCs grew as spheres in serum-free con-
ditions and DGCs expanded as adherent monolayers 
under serum-containing conditions. Elevated tissue ten-
sion induces a mesenchymal-like phenotype in GBM [3]. 
Thus, elevated stiffness may promote YAP/TAZ/TEAD 
activation of DGCs in GBM tissue.
CCN1, a transcriptional target of YAP/TAZ/TEAD, is 
secreted from various cell type, including, tumor cells, 
endothelial cells, fibroblasts, and smooth muscle cells 
[19, 36, 40]. CCN1 has been implicated in various cellular 
processes including leukocyte infiltration, inflammatory 
process, angiogenesis, and adhesion [19, 25, 30, 36, 53]. 
Moreover, we and others have revealed an elevation of 
CCN1 expression and its correlation with a poor progno-
sis in various tumors including GBM [9, 27, 35, 36]. How-
ever, which subpopulations of heterogeneous GBM cells 
secrete CCN1 and its detailed role in the heterogeneous 
GBM microenvironment has not been fully elucidated. 
We found that CCN1 was secreted abundantly from a 
population of DGCs, but not GSCs, which played criti-
cal roles in shaping the mesenchymal phenotype through 
macrophage infiltration into GBM tissue.
The gene signature of in  vitro culture models should 
be interpreted with caution because in  vitro DGC and 
Fig. 7 CCN1 secreted from DGCs augments macrophage infiltration through integrins. a Correlation analysis of mRNA expression of CCN1-binding 
integrins (ITGAV, ITGB3, ITGB5, ITGAM, ITGB2, ITGA6, and ITGB1) with DGC ssGSEA scores and mRNA expression of CCN1 in TCGA GBM (HG-U133A) 
dataset. Size and color indicate the correlation R-value. Pearson’s correlation test. b Correlation analysis of ITG (CCN1-binding integrin) ssGSEA 
scores with mRNA expression of CCN1 (left panel) and DGC ssGSEA scores (right panel) in TCGA GBM (HG-U133A) dataset. Red numbers indicate 
the correlation R-value and P value. Pearson’s correlation test. c Heat map shows expression of DGC, GSC, and ITG ssGSEA scores (top, second, and 
third from top) for each RNA sample in the anatomical structure study dataset (122 RNA sample data from 10 patients) from the IVY GAP database 
(columns). The corresponding GBM subtype and histology for each sample are labeled (bottom and second from bottom). d ssGSEA scores of ITG 
(CCN1-binding integrin) signature genes in multiple regions of the IVY GAP dataset (122 RNA sample data from 10 patients). Violin plots represents 
the median (thick dotted line) and quartiles (dotted line). **P < 0.01, ****P < 0.0001, one-way ANOVA with Tukey’s multiple comparisons test. e 
Schematic diagram showing the domain structure of wildtype CCN1 and D125A and DM mutants disrupted in binding sites for αvβ3/αvβ5 and 
αMβ2/α6β1 integrins, respectively. f Representative image (left panel) and quantification (right panel) of transwell analysis of U937 macrophages 
upon stimulation with conditioned medium (CM) from MGG8 DGCs with the indicated modification. Scale bar, 100 μm. n = 4 biological replicates, 
mean ± SEM, ****P < 0.0001, one-way ANOVA with Tukey’s multiple comparisons test. g Representative confocal images of tumor-bearing 
brains harvested at 30 days after implantation of 1 × 103 GSCs plus 1 × 104 matched DGCs from MGG8 cells with the indicated modification by 
a lentivirus. Scale bar, 100 µm. Iba1 (red), CD206 (green), and DAPI (blue). h Quantitation of pan-macrophages  (Iba1+) and M2 macrophages 
 (CD206+) densities in xenografts formed by 1 × 103 GSCs plus 1 × 104 matched DGCs from MGG8 cells with the indicated modification by a 
lentivirus. The total number of macrophages was counted in five randomly selected fields per sample. n = 5, mean ± SEM, ****P < 0.0001, ns: not 
significant, one-way ANOVA with Tukey’s multiple comparisons test. i Quantitation of the fraction of M2 macrophages  (CD206+). The fraction 
was determined by M2 macrophages  (CD206+) among pan-macrophages  (Iba1+) in xenografts formed by 1 × 102 GSCs plus 1 × 104 matched 
DGCs from MGG8 cells with the indicated modification by a lentivirus. The total number of macrophages was counted in five randomly selected 
fields per sample. n = 5 biological replicates. Data are represented as means ± SEM. *P < 0.05, **P < 0.01, ns: not significant, one-way ANOVA with 
Tukey’s multiple comparisons test. j Representative H&E stainings of tumor-bearing brains harvested at 30 days after implantation of 1 × 103 GSCs 
plus 1 × 104 matched DGCs from MGG8 cells with the indicated modification by a lentivirus. Scale bars, 2000 µm. k Kaplan–Meier (upper) and 
log-rank P value (bottom) analyses of mice bearing orthotopic xenografts of 1 × 103 GSCs plus 1 × 104 matched DGCs from MGG8 cells with the 
indicated modification by a lentivirus. l Kaplan–Meier analyses between patients in CCN1-high and CCN1-low groups on the basis of median mRNA 
expression in TCGA GBM dataset (HG-UG133A). Log-rank P value analyses. m Kaplan–Meier analyses of patients in TCGA GBM dataset (HG-UG133A) 
on the basis of ssGSEA scores of ITG (CCN1-binding integrin) signature genes. Log-rank P value analyses. n Negative correlation between expression 
of CCN1 combined with ITG (CCN1-binding integrin) signature genes and overall patient survival in TCGA GBM (HG-U133A) dataset. Log-rank P 
value analyses. o Negative correlation between expression of DGC-signature genes combined with ITG (CCN1-binding integrin) signature genes 
and overall patient survival in TCGA GBM (HG-U133A) dataset. Log-rank P value analyses
(See figure on next page.)
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GSC models do not fully recapitulate the heterogeneity 
of tumor cells within primary GBMs. However, a prior 
study applied a stemness signature of in  vitro culture 
models to GBM single cell transcriptional profiles and 
revealed the existence of cell subpopulations emulated 
by in vitro culture models within a primary tumor [38]. 
Interestingly, each in vitro model represents phenotypic 
extremes of the stemness gradients within GBM tumors 
[38]. Using other deposited GBM single cell RNA-
sequencing data, we also found clear gradients of DGC 
and GSC signatures and negative correlations between 
these signatures in each sample. These results reflect the 
validity of our approach using the DGC gene signature of 
in vitro culture models to investigate the biological roles 
of DGCs in GBMs.
Stem cell-like tumor-initiating cells expressing markers 
of proneural and mesenchymal transcriptomic subtypes 
(proneural and mesenchymal GSCs, respectively) have 
been reported in GBM [29]. In the present study, we used 
the proneural subtype of GSC models [51]. The biologi-
cal phenotype and anatomical distribution of proneural 
and mesenchymal GSCs are different [29]. Accordingly, 
in the future, studies that focus on the differences among 
proneural GSCs, mesenchymal GSCs, and DGCs from 
each subtype of GSCs are needed.
A limitation of the present study is that immune 
responses, including microglia/macrophages, are differ-
ent in immunocompetent and immunodeficient mice. 
BALB/c-nu/nu mice have impaired T-cell functions 
and an active macrophage system [12]. Therefore, in the 
future, we should perform in  vivo experiments using 
immunocompetent syngeneic mouse models.
In conclusion, our results reveal that DGCs contribute 
GSC-dependent tumor progression by shaping a mesen-
chymal microenvironment via macrophage infiltration 
and provide a new insight into the complex GBM micro-
environment consisting of heterogeneous mixtures of 
cells.
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